TY - JOUR
T1 - Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes
AU - Yeter, Hasan Haci
AU - Altunok, Murat
AU - Cankaya, Erdem
AU - Yildirim, Saliha
AU - Akturk, Serkan
AU - Bakirdogen, Serkan
AU - Akoğlu, Hadim
AU - Bulut, Mesudiye
AU - Sahutoglu, Tuncay
AU - Erdut, Arda
AU - Ozkahya, Mehmet
AU - Koc, Yener
AU - Tunca, Onur
AU - Kara, Ekrem
AU - Erek, Müge
AU - Polat, Mehmet
AU - Akagun, Tulin
AU - Guz, Galip
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature B.V. 2024.
PY - 2024/9
Y1 - 2024/9
N2 - Purpose: Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes. Methods: All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week. Results: A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001). Conclusion: IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period.
AB - Purpose: Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes. Methods: All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week. Results: A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001). Conclusion: IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period.
KW - Incremental peritoneal dialysis
KW - Peritoneal glucose exposure
KW - Residual kidney function
UR - https://www.scopus.com/pages/publications/85193025100
U2 - 10.1007/s11255-024-04077-7
DO - 10.1007/s11255-024-04077-7
M3 - Article
C2 - 38740705
AN - SCOPUS:85193025100
SN - 0301-1623
VL - 56
SP - 3123
EP - 3132
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 9
ER -